Uzbekistan Launches Incentives to Boost Pharmaceutical Industry

Tashkent, Uzbekistan (UzDaily.com) — President Shavkat Mirziev signed a decree on March 5, 2026, introducing additional measures to stimulate Uzbekistan’s pharmaceutical industry and enhance research and development processes.

The decree sets ambitious targets for 2026, including increasing production to 8.5 trillion soums, launching investment projects worth $1 billion, and initiating new projects valued at $800 million.

Under the decree, after the expiration of patents on original drugs, manufacturers will receive compensation of 50% of technology transfer costs (up to $50,000) or 50% of research and development expenses for product creation (up to $100,000).

From 1 January 2027, enterprises with a national GMP certificate will be permitted to produce dietary supplements on their certified production lines throughout the certificate’s validity. Starting from 1 June 2026, companies with tax arrears up to twice the basic calculation rate may participate in government procurement; larger arrears can be resolved within 10 days.

By 1 January 2028, the HAACP system will become mandatory for the approval of dietary supplements, which will also be subject to digital labeling.

To strengthen the country’s scientific capacity, the decree establishes the National Research Institute of Biopharmaceuticals, based on the Uzbek Institute of Chemical and Pharmaceutical Research, the Tashkent Institute of Vaccine and Serum Research, and the Institute of Eastern Medicine, aimed at boosting the research and innovation base of the sector.